Cyber risk, climate change, new pharmaceutical therapies—as companies look for ways to manage increasing costs and unforeseen exposures, captives are a popular mechanism to insure against the unexpected. Around since the 1950s, today there are more than 7,000 captive insurers worldwide, with many headquartered in Vermont, Bermuda, and the Cayman Islands. As these insurance vehicles grow in popularity, Milliman experts answer the top 10 questions everyone’s asking about captives.

You can read the episode transcript on our website.

Drugmakers are taking steps to make sure clinical trials include participants from a variety of backgrounds—and they are steadily making progress, as evidenced by new studies of multiple sclerosis and sickle cell disease. Milliman health researchers Ellyn Russo and Chris Page unpack a history of distrust in medical research, the implications of failing to attract diverse study participants, and how simple strategies like rideshare vouchers, childcare, and check-in apps can help expand a study’s reach, so more patients have access to the latest treatments and medical research moves forward.

You can read the episode transcript on our website.

Life insurers have historically invested their portfolios in the relative safety of mortgages and bonds, but economic volatility, sticky inflation, and other headwinds have spurred many insurance companies to diversify into alternatives, a trend explored in a recent Milliman paper. On this episode of Critical Point, three of the paper’s authors discuss two alternative asset classes that are particularly attractive to insurers in today’s market: private equity and real estate. They talk about unexpected assets like student housing and storage facilities, the synergy of private equity firms investing in insurers and vice versa, and why many insurance companies continue to hold commercial real estate despite post-pandemic office vacancies.

You can read the episode transcript on our website.